Rice Hall James & Associates’s AtriCure ATRC Stock Holding History

Rice Hall James & Associates’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76M	Buy	134,207 +108,997	+432%	+$3.07M	0.18%	126
2026 Q1	$719K	Buy	+25,210	New	+$860K	0.04%	208
2020 Q4	–	Sell	-24,641	Closed	-$983K	–	301
2020 Q3	$983K	Buy	24,641 +2,222	+10%	+$94.2K	0.04%	230
2020 Q2	$1.01M	Buy	22,419 +100	+0.4%	+$4.35K	0.04%	211
2020 Q1	$750K	Sell	22,319 -21,668	-49%	-$779K	0.04%	219
2019 Q4	$1.43M	Sell	43,987 -839	-2%	-$23.9K	0.05%	206
2019 Q3	$1.12M	Buy	+44,826	New	+$1.28M	0.04%	226

Other funds holding ATRC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rice Hall James & Associates's ATRC Position: Q2 2026 in Review

Rice Hall James & Associates increased its AtriCure (ATRC) stake by 432% in Q2 2026, buying an estimated $3.07M and bringing the position to 134,207 shares worth $3.76M. The position accounts for 0.18% of the portfolio, ranked #126.

Rice Hall James & Associates first reported a position in ATRC in Q3 2019 and has held it in 7 quarters since. 251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

Rice Hall James & Associates held 134,207 shares of AtriCure worth $3.76M as of Q2 2026.
Rice Hall James & Associates bought 108,997 AtriCure shares in Q2 2026, an estimated $3.07M.
AtriCure made up 0.18% of Rice Hall James & Associates's portfolio in Q2 2026, its #126 holding.
Rice Hall James & Associates first reported a position in AtriCure in Q3 2019 and has held it in 7 quarters since.
251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.